Squarepoint
ALNY icon

Squarepoint’s Alnylam Pharmaceuticals ALNY Stock Holding History

Squarepoint’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.19M Sell
23,900
-45,200
-65% -$13.6M 0.01% 1324
2026
Q1 		$22.9M Sell
69,100
-4,000
-5% -$1.36M 0.03% 633
2025
Q4 		$29.1M Buy
73,100
+55,200
+308% +$24.4M 0.03% 587
2025
Q3 		$8.16M Buy
17,900
+15,400
+616% +$6.27M 0.01% 1180
2025
Q2 		$815K Buy
2,500
+400
+19% +$111K ﹤0.01% 2841
2025
Q1 		$567K Sell
2,100
-21,200
-91% -$5.45M ﹤0.01% 3177
2024
Q4 		$5.48M Buy
23,300
+15,200
+188% +$4M 0.01% 1560
2024
Q3 		$2.23M Buy
+8,100
New +$2.11M ﹤0.01% 1990
2024
Q2 		– Sell
-20,000
Closed -$2.99M – 4011
2024
Q1 		$2.99M Buy
+20,000
New +$3.34M 0.01% 1827
2021
Q2 		– Sell
-13,200
Closed -$1.86M – 3188
2021
Q1 		$1.86M Buy
+13,200
New +$1.99M 0.01% 1113

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint's ALNY Position: Q2 2026 in Review

Squarepoint reduced its Alnylam Pharmaceuticals (ALNY) stake by 45% in Q2 2026, selling an estimated $58.1M and leaving 233,999 shares worth $70.4M. The position accounts for 0.08% of the portfolio, ranked #249.

Squarepoint first reported a position in ALNY in Q4 2015 and has held it in 34 quarters since. The position peaked at $141M in Q1 2026. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Squarepoint held 233,999 shares of Alnylam Pharmaceuticals worth $70.4M as of Q2 2026.
  • Squarepoint sold 192,724 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $58.1M.
  • Alnylam Pharmaceuticals made up 0.08% of Squarepoint's portfolio in Q2 2026, its #249 holding.
  • Squarepoint first reported a position in Alnylam Pharmaceuticals in Q4 2015 and has held it in 34 quarters since.
  • Squarepoint's Alnylam Pharmaceuticals position peaked at $141M in Q1 2026.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.